Wechselwirkungen · Hetlioz
HETLIOZ 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 3–4
HOS-132637 · Präparat HOS-097266
Potential for other medicinal products to affect tasimelteon CYP1A2 and CYP3A4 are enzymes identified to play a role in the metabolism of tasimelteon, with a minor role for CYP2C9/C19. Medicinal products that inhibit CYP1A2 and CYP3A4 have been shown to alter the metabolism of tasimelteon in vivo. 3 Strong CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin and enoxacin) Caution should be used when administering tasimelteon in combination with fluvoxamine or other strong CYP1A2 inhibitors such as ciprofloxacin and enoxacin because of a potentially large increase in tasimelteon exposure and greater risk of adverse reactions: the AUC0-inf and Cmax of tasimelteon increased by 7-fold and 2-fold, respectively, when co-administered with fluvoxamine 50 mg (after 6 days of fluvoxamine 50 mg per day). This is deemed even more important for strong CYP1A2 inhibitors also inhibiting other enzymes involved in the clearance of tasimelteon (e.g. fluvoxamine and ciprofloxacin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ciprofloxacin (HOS-085177) enoxacin (HOS-111703) fluvoxamine (HOS-085908)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-10-11T10:36:00Z · SHA-256 0bdd018612638920216d61b9df071c2e9fc23b79e4c4fa60fe93516eca4a47ff · Passage ce056a4c9ef6eeeb7e42a6b0d000b530e4b80f9bbfd5a77d88587e1053f9067f · Zeichen 0–1032 im Abschnitt